Skip to main content
Log in

Neuritis nervi optici

Optic nerve neuritis

  • CME Zertifizierte Fortbildung
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Die Neuritis nervi optici ist eine der wichtigsten Differenzialdiagnosen der akuten Sehverschlechterung im jungen und mittleren Erwachsenenalter. Die Diagnose wird klinisch gestellt. Die funktionelle Prognose der Erkrankung ist grundsätzlich gut. Steroide verkürzen das Erholungsintervall, ändern jedoch nichts an der funktionellen Langzeitprognose. Wichtigste Untersuchung zur Abschätzung eines möglichen Multiple-Sklerose-Risikos ist die Magnetresonanztomographie. Die optische Kohärenztomographie liefert zusätzliche Hinweise auf Verlauf und Funktion nach Neuritis nervi optici und kann in Zukunft vielleicht weitere Zusammenhänge zwischen Neuritis nervi optici und evtl. multipler Sklerose liefern.

Abstract

Optic nerve neuritis is one of the most important differential diagnoses of visual loss in young and middle aged adults. The prognosis in terms of functional outcome is generally good. The diagnosis of optic neuritis is clinical. Steroids can reduce the recovery time but do not affect the long-term functional outcome. Magnetic resonance imaging (MRI) is the most important investigation for assessing an associated risk of multiple sclerosis. Optical coherence tomography (OCT) contributes additional details on the course and functional outcome of optic neuritis. In the future OCT may additionally contribute to the relationship between optic neuritis and possible associated multiple sclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Abbreviations

MRT:

Magnetresonanztomographie

MS:

multiple Sklerose

NNO:

Neuritis nervi optici

OCT:

optische Kohärenztomographie

VEP:

visuell evozierte Potenziale

Literatur

  1. Beck RW (1992) The optic neuritis treatment trial. Implications for clinical practice. Optic Neuritis Study Group. Arch Ophthalmol 110(3):331–332

    Article  PubMed  CAS  Google Scholar 

  2. Beck RW, Gal RL (2008) Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial. Arch Ophthalmol 126(7):994–995

    Article  PubMed  Google Scholar 

  3. Volpe NJ (2008) The optic neuritis treatment trial: a definitive answer and profound impact with unexpected results. Arch Ophthalmol 126(7):996–999

    Article  PubMed  Google Scholar 

  4. Roed HG et al (2005) A double-blind, randomized trial of iv immunoglobulin treatment in acute optic neuritis. Neurology 64(5):804–810

    Article  PubMed  CAS  Google Scholar 

  5. Tselis A et al (2008) Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 15(11):1163–1167

    Article  PubMed  CAS  Google Scholar 

  6. Comi G et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268):1576–1582

    Article  PubMed  CAS  Google Scholar 

  7. Comi G et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374(9700):1503–1511

    Article  PubMed  CAS  Google Scholar 

  8. Kappos L et al (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8(11):987–997

    Article  PubMed  CAS  Google Scholar 

  9. Jacobs LD et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343(13):898–904

    Article  PubMed  CAS  Google Scholar 

  10. Kinkel RP et al (2006) IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66(5):678–684

    Article  PubMed  Google Scholar 

  11. Wingerchuk DM et al (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6(9):805–815

    Article  PubMed  CAS  Google Scholar 

  12. Ratchford JN et al (2009) Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 73(4):302–308

    Article  PubMed  CAS  Google Scholar 

  13. Costello F et al (2006) Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 59(6):963–969

    Article  PubMed  Google Scholar 

  14. Beck RW et al (2003) High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 121(7):944–949

    Article  PubMed  Google Scholar 

  15. Henderson AP et al (2010) A preliminary longitudinal study of the retinal nerve fiber layer in progressive multiple sclerosis. J Neurol 257(7):1083–1091

    Article  PubMed  Google Scholar 

  16. Petzold A et al (2010) Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 9(9):921–932

    Article  PubMed  Google Scholar 

  17. Naismith RT et al (2009) Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology 73(1):46–52

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

H. Steffen gibt an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H. Steffen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steffen, H. Neuritis nervi optici. Ophthalmologe 110, 783–794 (2013). https://doi.org/10.1007/s00347-013-2906-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-013-2906-y

Schlüsselwörter

Keywords

Navigation